Workflow
NeoGenomics(NEO)
icon
Search documents
Technical Update: NEO Battery Advances Silicon Anode Technology with Extended Battery Capacity Performance
GlobeNewswire News Room· 2024-08-13 13:30
TORONTO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTC: NBMFF) Silicon Anode Technology Advancement with Extended Capacity Performance & Sustained Low-Cost Advantage Record-High Battery Performance Metric that Meets or Exceeds Industry Standards and Similar Commercial Products Two-Way Coating Enhancement: Simple, Feasible, and Low-Cost Planned Release of New Silicon-Carbon (Si-C) Anode Product Due to High Working Party & Industry Demand Recycled Silicon Evaluation In-Progress with Lotus Energy & INNOX ...
NeoGenomics(NEO) - 2024 Q2 - Quarterly Report
2024-07-30 20:04
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 NEOGENOMICS, INC. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements ...
NEO Battery Provides Corporate Update on Product R&D, Advanced Testing, and Pathway-to-Commercialization
GlobeNewswire News Room· 2024-07-30 16:55
anodes to screen for compatibility. These tests will be the key to moving to the following stages with battery cell and EV manufacturers. This news release includes certain forward-looking statements as well as management's objectives, strategies, beliefs and intentions. All information contained herein that is not clearly historical in nature may constitute forward-looking information. Generally, such forward-looking information can be identified notably, but not limited to, by the use of forward-looking t ...
Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q2 Earnings
ZACKS· 2024-07-29 23:01
NeoGenomics (NEO) reported $164.5 million in revenue for the quarter ended June 2024, representing a yearover-year increase of 12%. EPS of $0.03 for the same period compares to -$0.05 a year ago. ...
NeoGenomics(NEO) - 2024 Q2 - Quarterly Results
2024-07-29 20:08
Exhibit 99.1 Fort Myers, Florida (July 29, 2024) - NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2024. Second-Quarter Results Net loss for the quarter decreased $6 million, or 23%, to $19 million compared to net loss of $24 million for the second quarter of 2023. Second Quarter Revenue Increased 12% to $165 Million Raising Revenue Guidance $655 to $667 Million and Adjusted EBITDA to $33 t ...
NEO Battery Establishes Collaboration Agreement with Lotus Energy to Strengthen Recycled Silicon Anode Initiative
GlobeNewswire News Room· 2024-07-26 12:15
TORONTO, July 26, 2024 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTC: NBMFF) NEO and Lotus intend to develop a silicon anode product to co-market directly to battery cell, electronics, and automotive manufacturers. Both companies will explore joint venture opportunities to establish a North American footprint in silicon recycling. Governmental funding for international cooperation will be applied for in advanced manufacturing and clean technology based on availability and criteria-match. Headquartered in Melbourne, ...
NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation
GlobeNewswire News Room· 2024-07-16 15:15
FDA approval reflects positive results from Phase I and preliminary results from Phase IIa study currently underway that demonstrate increased survivability rates in patients with the IDH1 marker. Trial expands from patients afflicted with Recurrent Grade IV Astrocytoma with IDH1 mutation to those with equally aggressive Recurrent Grade III Astrocytoma with IDH1 mutation. Enrollment in three other NeOnc clinical studies also advance after several published studies indicate the viability of NeOnc's NEO™ plat ...
AI-boosted medical diagnostics firm Tempus AI given 'buy' rating
Proactiveinvestors NA· 2024-07-09 18:27
Proactive has always been a forward looking and enthusiastic technology adopter. Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. About this content Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company I ...
NEO Battery Materials Forges Collaboration Agreement with Major South Korean Chemical Material Company, INNOX eco-M
GlobeNewswire News Room· 2024-06-11 12:30
TORONTO, June 11, 2024 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTC: NBMFF) Collaboration Agreement with INNOX eco-M – Leading South Korean Chemical Material Company of Recycled Silicon Powders Subsidiary of INNOX Holding Corp. – A Producer of Secondary Battery Materials and IT HighTech Materials with Investment Business Operations Jointly Developing Silicon Anode Products with INNOX eco-M's High-Purity Recycled Silicon Development Priorities: Enhance Electrochemical Performance, Lower Anode Manufacturing Costs & E ...
NeoGenomics(NEO) - 2024 Q1 - Quarterly Report
2024-04-30 20:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...